Frontier Pharma: Chronic, Acute and Neuropathic Pain – GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes: ResearchMoz

Albany, NY, Sept. 16, 2016 (GLOBE NEWSWIRE) —

Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain as a disease, rather than just as a symptom of a primary cause. In the US, pain affects more people than cancer, diabetes and heart disease combined, with an estimated 100 million people having experienced at least one chronic pain episode in the last 12 months, at an annual cost of around $600 billion in medical treatment and lost productivity.

For more info, get a Sample PDF: http://www.researchmoz.us/enquiry.php?type=S&repid=811826

The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established product categories, active pharmaceutical ingredients and concomitant mechanisms of action.

Moderate-to-severe pain has been and continues to be dominated by opioids, which are increasingly being reformulated to offer abuse-resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (NSAID). However, significant unmet needs remain, as chronic pain subtypes – and particularly neuropathic pain – do not respond well to existing therapies, which do not align to the underlying molecular pathophysiological profile of pain.

However, strong unmet needs remain in core therapy types such as NSAIDs, which are associated with often severe gastrointestinal adverse events (AE), and opioids, which have a range of AEs associated with them – in addition to the potential for abuse, which has not been fully alleviated by the development of abuse-deterrent formulations.

 

Scope

 

  • Analysis of innovation in the pain markets (including both nociceptive and neuropathic pain, of both a chronic and acute nature), in the context of the overall pipeline and current market landscape. Also includes analysis of the deals landscape surrounding first-in-class products in pain, and highlights opportunities for in-licensing.
  • A brief introduction to chronic and acute pain, including subtypes, symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
  • The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline.
  • Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.

 

View TOC (table of content), Figures and Tables of the Report: http://www.researchmoz.us/frontier-pharma-chronic-acute-and-neuropathic-pain-gpcr-and-nerve-growth-factorbased-therapies-offer-strong-potential-in-difficulttotreat-subtypes-report.html

 

Reasons to buy

 

  • Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
  • Visualize the composition of the pain markets in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
  • Analyze the pain pipeline, stratified by pain subtype, stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

 

Related Reports:-

 

Ø  United States Peripheral Neuropathic Pain Drug Industry 2016 Market Research Report: http://www.researchmoz.us/united-states-peripheral-neuropathic-pain-drug-industry-2016-market-research-report-report.html

 

Ø  China Peripheral Neuropathic Pain Drug Industry 2016 Market Research Report: http://www.researchmoz.us/china-peripheral-neuropathic-pain-drug-industry-2016-market-research-report-report.html

 

About Us

 

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

CONTACT: Rohit Bhisey
ResearchMoz Global Pvt. Ltd.
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-621-2074
USA - Canada Toll Free: 866-997-4948
Website: http://www.researchmoz.us/